Asadorian described the post-enrollment cadence: “it’s going to be about 4 weeks after we complete enrollment… to get to the top-line data,” followed by “another 3 months or so to get to that PMA ...

NEPHRO-CRRT enrollment reached 75%, with completion expected later in 2026. Talphera anticipates top-line data four to five weeks afterward and plans to submit a PMA for nafamostat in the first half ...

Talphera advanced NEPHRO-CRRT trial enrollment to 75%, targeting completion later in 2026. Cash balance of $17.1M and access to $16M in conditional financing support operations through a potential ...

Please provide your email address to receive an email when new articles are posted on . Patients who attempted to discontinue therapy earlier were older and had lower illness severity, among other ...

Management reported that the NEPHRO CRRT registrational study reached 75% enrollment while maintaining the targeted timeline for clinical data results. The company highlighted recent updates to ...